Overview of the Pharmacokinetics of Fluvoxamine

  title={Overview of the Pharmacokinetics of Fluvoxamine},
  author={Jaap van Harten},
  journal={Clinical Pharmacokinetics},
  • J. Harten
  • Published 1995
  • Medicine, Biology
  • Clinical Pharmacokinetics
SummaryThe pharmacokinetics of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) with antidepressant properties, are well established. After oral administration, the drug is almost completely absorbed from the gastrointestinal tract, and the extent of absorption is unaffected by the presence of food. Despite complete absorption, oral bioavailability in man is ≈ 50% on account of first-pass hepatic metabolism. Peak plasma fluvoxamine concentrations are reached 4 to 12 hours (enteric… 
Pharmacokinetics of selective serotonin reuptake inhibitors.
Pharmacokinetic considerations for current state-of-the-art antidepressants
  • E. Wyska
  • Psychology, Biology
    Expert opinion on drug metabolism & toxicology
  • 2019
The pharmacogenetic testing with concomitant application of TDM seems to be the best way for implementing personalized dosing of current state-of-the-art antidepressants metabolized by polymorphic CYPs, especially when co-administered with strong inhibitors or other substrates of CYP2D6 or CYP 2C19.
Selective Serotonin Reuptake Inhibitors and CNS Drug Interactions
In vitro and in vivo evidence for drug interactions between SSRIs and other central nervous system drugs is reviewed, with special emphasis on antipsychotics, tricyclic anti-depressants and benzodiazepines.
In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine
In schizophrenic patients, FLV resulted in a pronounced increased in CLZ plasma concentrations with the total mean CLZ AUC increased by a factor of 2.58, indicating that in-vitro evaluations may not always accurately reflect changes in drug-drug interaction observed in- vivo.
Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.
Fluvoxamine has demonstrated short term efficacy in the treatment of OCD, panic disorder, social phobia, PTSD and in a range of obsessive-compulsive spectrum disorders and appears to have a better tolerability profile.
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions
A database containing information about the clearance routes for over 300 drugs from multiple therapeutic classes, including analgesics, anti-infectives, psychotropics, anticonvulsants, cancer chemotherapeutics, gastrointestinal agents, cardiovascular agents and others, was constructed to assist in the semiquantitative prediction of the magnitude of potential interactions with drugs under development.
Clinical impact of fluvoxamine-mediated long QTU syndrome
In vitro experiments strongly indicate that clozapine blocks HERG channels, even at physiological concentrations, suggesting this mechanism to have an important arrhythmogenic impact in clozabine-treated patients, and the proarrhythmic effects of the atypical antipsychotic clozAPine have been well known for many years.
The Amount of Fluvoxamine in Milk Is Unlikely to Be a Cause of Adverse Effects in Breastfed Infants
Limited data support the prescription of fluvoxamine to breastfeeding mothers after a careful, individual risk/benefit analysis is undertaken and no adverse effects were detected by the mother or on clinical examination.


Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers
Fluvoxamine inhibits the biotransformation of diazepam and its active N‐demethylated metabolite, and the magnitude of this interaction is likely to have considerable clinical significance.
Effect of Fluvoxamine on the Pharmacokinetics of Imipramine and Desipramine in Healthy Subjects
Findings indicate that, at the dosage tested, fluvoxamine markedly inhibits the demethylation of imipramine without affecting significantly the CYP2D6-mediated hydroxylation of desipramines.
Pharmacokinetics of Fluvoxamine Maleate in Patients with Liver Cirrhosis after Single-Dose Oral Administration
It is concluded that in patients with signs of active liver disease, e.g. raised bilirubin, it is wise to lower the initial daily dose and to carefully monitor the patient during subsequent upward dose adjustments.
Pharmacokinetic Optimisation of Therapy with Newer Antidepressants
  • P. Goodnick
  • Medicine, Biology
    Clinical pharmacokinetics
  • 1994
The antidepressants best suited for pharmacokinetic optimisation of therapy are the following: desipramine, sertraline, fluvoxamine, citalopram and amfebutamone, which stands out as having the best effects on behaviour among all antidepressants.
Bioavailability of fluvoxamine given with and without food
The influence of concomitant food intake on plasma concentrations of the antidepressant drug fluvoxamine maleate was investigated in a two‐way, crossover study design and it was concluded that the effect of food on the pharmacokinetics of fluv oxamine is negligible.
Clinical Pharmacokinetics of Selective Serotonin Reuptake Inhibitors
Although many attempts were made, to date no convincing evidence exists of a relationship between plasma concentrations of any of the SSRIs and clinical efficacy, and available data indicate that metabolism ofSSRIs is impaired with reduced liver function.
Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.
Fluvoxamine may be particularly beneficial in potentially suicidal patients with severe depression, in those with an underlying compulsive personality or cardiovascular disorder, in patients with coexistent anxiety or agitation, and in the elderly.
Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.
Fluoxetine has overall therapeutic efficacy comparable with imipramine, amitriptyline and doxepin in patients with unipolar depression treated for 5 to 6 weeks, although it may be less effective than tricyclic antidepressants in relieving sleep disorders in depressed patients.
Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects
Plasma concentrations increased in a linear dose‐dependent manner in the dose range between 25 and 100 mg; t1/2 and Tmax showed no significant differences among treatments; Fluvoxamine was well tolerated.